1. Otezla (apremilast), manufactured by Summit, N.J.-based Celgene Corp., has been approved as a treatment for psoriatic arthritis in adults.
2. Xolair (omalizumab), co-developed and co-promoted by San Francisco-based Genentech and East Hanover, N.J.-based Novartis, has been approved to treat a chronic form of hives.
3. The FDA has approved Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) to be used as a preventative measure against potential pulmonary embolism-causing blood clots for patients who have undergone hip or knee replacement therapy.
4. The FDA has approved Myalept, metreleptin for injection, as a treatment option for patients with congenital generalized or acquired generalized lipodystrophy, a condition where patients have little to no fat tissue.
More Articles on Pharmaceuticals:
Pacira Joins NPSF Coalition
OxyContin Manufacturer Creates Tamper-Resistant Hydrocodone Drug
New Drugs Funneled $4B Into Exchange-Traded Funds in 2014
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
